Therefore, we conducted an open-label, multicenter, single-arm phase II study to evaluate the effectiveness and safety of osimertinib in patients with EGFR T790M mutation-positive advanced NSCLC with Eastern Cooperative Oncology Group (ECOG) PS scores of 2–4. Here, EGFR is linked to non-small cell lung carcinoma.